Q-omics provides the consensus-scored SNHG22 profile across patient tissues and cancer cell-line models. SNHG22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SNHG22 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SNHG22 RNA expression shows 15,614 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where SNHG22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG22 survival associations across molecular data types. SNHG22 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG22 RNA expression–survival associations across cancer types. High SNHG22 expression shows unfavorable associations in KIRC, LUAD and PRAD, but favorable associations in BRCA, SKCM and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for SNHG22 RNA expression.
This table summarizes SNHG22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG22 shows higher tumor expression in KIRC, LIHC, COAD, THCA, HNSC and STAD. The KIRC box plot shows higher SNHG22 RNA expression in tumor versus normal tissue (log2 FC = +0.466, t-test p < 0.001).
This table shows molecular features associated with SNHG22 in patient tissues and cancer cell lines. In patient samples, SNHG22 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
